Cargando…
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
SIMPLE SUMMARY: Immunotherapy has changed the treatment paradigm of numerous malignancies such as non-small cell lung cancer and melanoma. To date, there has been only modest demonstrable efficacy of immunotherapy for prostate cancer. This lack of efficacy is likely due to the immunosuppressive tumo...
Autores principales: | Bansal, Dhruv, Reimers, Melissa A., Knoche, Eric M., Pachynski, Russell K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831137/ https://www.ncbi.nlm.nih.gov/pubmed/33477569 http://dx.doi.org/10.3390/cancers13020334 |
Ejemplares similares
-
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015) -
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020) -
Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017) -
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
por: Drake, Charles G., et al.
Publicado: (2021) -
Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)